AT A GLANCE

A new study published in Nature Medicine confirms the potential of sonelokimab (SLK) for treatment of psoriatic arthritis (PsA).¹

“PsA is a progressive, multidomain and interleukin-17 (IL-17)-linked disease that results in substantial quality-of-life deficits,” explain study authors McInnes et al. “Thereby, we conducted a phase 2 randomized, double-blind, placebo (PBO)-controlled trial of SLK, a nanobody that binds with a similarly high affinity to IL-17A and IL-17F, inhibiting all dimers.”

For study purposes, 207 patients with active PsA were randomized to SLK 120-mg or 60-mg every 4 weeks (Q4W; both with induction [WI]) 60-mg Q4W with no induction, PBO, or adalimumab (reference arm).

According to the authors, the primary endpoint of interest, American College of Rheumatology (ACR) 50 at week 12, was met for both SLK 60-mg and 120-mg WI. Further, SLK therapy resulted in significant benefits across the key secondary endpoints of ACR20 and Psoriasis Area and Severity Index (PASI) 90 at Week 12.

The authors add that robust responses were observed among patients randomized to SLK at Week 24 for the high-threshold composite endpoints of ACR70 + PASI 100 (exploratory) and minimal disease activity (secondary), which were achieved by up to 48% (13/27; 120-mg WI) and 61% (25/41; 60-mg WI) of patients, respectively.

“Overall, SLK delivered substantial improvements in the signs and symptoms of PsA across various outcomes and domains,” conclude the authors.

Reference

1.     McInnes IB, Coates LC, Mease PJ, et al. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial (online ahead of print October 6, 2025). Nat Med.